目的 探討谷紅注射液聯(lián)合依帕司他治療糖尿病周圍神經(jīng)病變的臨床研究。方法 選取2022年10月—2024年10月武漢市中醫(yī)醫(yī)院收治的98例糖尿病周圍神經(jīng)病變患者，按照隨機(jī)數(shù)字法將患者分為對照組和治療組，每組各49例。對照組患者給予依帕司他片，50 mg/次，3次/d。治療組在對照組的基礎(chǔ)上給予谷紅注射液，10 mL加入0.9%氯化鈉注射液200 mL中稀釋后靜脈滴注，1次/d。兩組用藥28 d。觀察兩組的臨床療效和臨床癥狀緩解時間，比較兩組治療前后餐后2 h血葡萄糖（2 hPG）、空腹血漿葡萄糖（FPG）、糖化血紅蛋白（HbA1c）、多倫多臨床系統(tǒng)評分（TCSS）、視覺模擬疼痛（VAS）評分法、同型半胱氨酸（Hcy）、血清超氧化物歧化酶（SOD）、胰島素樣生長因子-1（IGF-1）、血清胱抑素C（Cys-C）水平。結(jié)果 治療后，治療組總有效率是97.96%，顯著高于對照組的81.63%（P＜0.05）。治療后，與對照組對比，治療組手腳麻木、局部刺痛、肌肉無力、異常出汗緩解時間均較短（P＜0.05）。治療后，兩組患者2 hPG、FPG、HbA1c水平均顯著降低（P＜0.05）；治療后，與對照組對比，治療組2 hPG、FPG、HbA1c水平均較低（P＜0.05）。治療后，兩組TCSS評分、VAS評分均顯著降低（P＜0.05）；治療后，與對照組對比，治療組TCSS評分、VAS評分均較低（P＜0.05）。治療后，兩組Hcy、Cys-C水平顯著降低，而SOD、IGF-1顯著升高（P＜0.05）；治療后，與對照組對比，治療組Hcy、Cys-C水平均較低，而SOD、IGF-1水平較高（P＜0.05）。結(jié)論 谷紅注射液聯(lián)合依帕司他治療糖尿病周圍神經(jīng)病變的協(xié)同治療療效明顯，緩解神經(jīng)病變癥狀及疼痛，可有效保護(hù)神經(jīng)組織，并能改善局部血液微循環(huán)，抑制炎癥反應(yīng)，值得借鑒應(yīng)用。

Objective To investigate the therapeutic effect of Guhong Injection combined with epalrestat in treatment of diabetic peripheral neuropathy.Methods A total of 98 patients with diabetic peripheral neuropathy admitted to Wuhan Hospital of Traditional Chinese Medicine from October 2022 to October 2024 were selected. The patients were divided into control group and treatment group according to random number method, with 49 cases in each group. Patients in control group were given Epalrestat Tablets, 50 mg each time, three times daily. Patients in treatment group were given Guhong Injection on basis of control group. 10 mL was diluted with 200 mL of 0.9% sodium chloride injection and then intravenously infused once daily. The two groups were treated for 28 d. The clinical efficacy and the remission time of clinical symptoms of two groups were observed. The change of 2 hPG, FPG, HbA1c, TCSS score, VAS score, Hcy, SOD, IGF-1, and Cys-C before and after treatment in two groups were compared.Results After treatment, the total effective rate of treatment group was 97.96%, significantly higher than 81.63% of control group (P < 0.05). After treatment, compared with control group, the relief time of numbness in hands and feet, local tingling pain, muscle weakness and abnormal sweating in treatment group was shorter (P < 0.05). After treatment, the levels of 2 hPG, FPG, and HbA1c in both groups were significantly decreased (P < 0.05). After treatment, compared with control group, the levels of 2 hPG, FPG, and HbA1c in treatment group were all lower (P < 0.05). After treatment, the TCSS scores and VAS scores of both groups decreased significantly (P < 0.05). After treatment, compared with control group, the TCSS score and VAS score of treatment group were both lower (P < 0.05). After treatment, the levels of Hcy and Cys-C in both groups decreased significantly, but SOD and IGF-1 increased significantly (P < 0.05). After treatment, compared with control group, the levels of Hcy and Cys-C in treatment group were lower, but the levels of SOD and IGF-1 were higher (P < 0.05).Conclusion The synergistic therapeutic effect of Guhong Injection combined with epalastat in treatment of diabetic peripheral neuropathy is obvious, and can relieve the symptoms and pain of neuropathy, effectively protect nerve tissue, improve local blood microcirculation, and inhibit inflammatory responses. It is worthy of reference and application.

R971

湖北省衛(wèi)生健康委員會中醫(yī)藥科研項目（ZY2021Q037）